汕头24岁女子查出白癜风潮州市治白癜风哪家比较好,汕尾哪里看白癜风比价好,梅州皮肤白癜风能治好吗,揭阳哪里治白癜风治的靠谱,梅州医生治疗白癜风好吗,汕尾哪里治疗白癜风更权威,汕尾白癜风治疗哪个有名

BEIJING, Oct. 26 (Xinhua) -- The central government allocated 935 million yuan (147 million U.S. dollars) Wednesday to areas hit by rain-triggered floods, the Ministry of Civil Affairs (MCA) said.The relief funds, jointly allocated by the MCA and the Ministry of Finance, will be used for disaster survivors to relocate, rebuild houses and buy daily necessities.The funds will also be delivered to the family members of the victims, according to the ministry.The funds will go to the flood-hit provinces of Shanxi, Henan, Hubei, Sichuan, Shanxi and Guangxi Zhuang Autonomous Region.The government already allocated 132 million yuan (20.6 million U.S. dollars) to disaster hit areas immediately after the floods happened in September.Rain-triggered floods and disasters left 97 people dead, 21 missing and 1.23 million affected in September in China's 11 provincial-level regions, and a total of 1.93 million people were relocated urgently to avoid further casualties.The disasters also caused an estimated 21 billion yuan (3.29 billion U.S. dollars) in direct economic losses, according to official data.

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

WASHINGTON, Dec. 12 (Xinhua) -- British scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth. The findings, published Monday in the U.S. journal Cancer Cell, reveal how cancer cells grow faster by producing their own blood vessels.Cancer cells gain the nutrients they need by producing proteins that make blood vessels grow, helping deliver oxygen and sugars to the tumor. These proteins are vascular growth factors like VEGF -- the target for the anti-cancer drug Avastin. Making these proteins requires the slotting together of different parts of genes, a process called splicing.Scientists at the University of West England and the University of Bristol discovered that mutations in one specific cancer gene can control how splicing is balanced, allowing a master switch in the cell to be turned on. This master switch of splicing makes cancer cells grow faster, and blood vessels to grow more quickly, as they alter how VEGFs are put together.In experimental models, the researchers found that by using new drugs that block this master switch they prevented blood vessel growth and stopped the growth of cancers."The research clearly demonstrates that it may be possible to block tumor growth by targeting and manipulating alternative splicing in patients, adding to the increasingly wide armory of potential anti-cancer therapies," the authors said.

BEIJING, Jan. 21 (Xinhua) -- A locomotive producer in central China's Hunan province on Friday rolled out a low-cost magnetically levitated (maglev) train that is more environmental-friendly than conventional ones.The three-carriage train is designed to run at a maximum speed of 100 km per hour and carry 600 passengers, said Xu Zongxiang, general manager of Zhuzhou Electric Locomotive Co. Ltd. of China South Locomotive and Rolling Stock Corporation (CSR). Xu said the new train was much quieter than conventional ones. While a conventional train moves forward by using friction between its wheels and the railway tracks, the maglev train replaces wheels by electromagnets and levitates on the guideway. According to Xu, his company's has minimized the risk of the new maglev train derailing or overturning. "It's ideal for mass transportation, as it is quiet and environmental-friendly. Its manufacturing cost is about 75 percent of a conventional light-rail train," said Xu. The maglev train has a minimum turning radius of 50 meters and can easily run in residential communities or on hilly slopes. "It's an ideal public transport option for Chinese cities and major tourist destinations," said Xu. Railway transport specialist Liu Youmei, also an academician with Chinese Academy of Engineering, said the new train is green, economical and safe. "It can be used for public transport in populous areas and at scenic spots with fragile environments." Liu said China is one of a few countries that have applied maglev technology. Beijing is building a maglev route, the Daitai line (S1), which starts at its IT center in Haidian district, passes through Shijingshan district, and ends in Mentougou district on its western outskirts. The line will be operational next year.The eastern metropolitan of Shanghai runs the world's first commercial maglev system on a 30-km stretch between the downtown business district and Pudong airport. The German-made maglev went into operation on Dec. 31, 2002.

WASHINGTON, Oct. 19 (Xinhua) -- A total of 25 people have been killed in 12 U.S. states in a listeria outbreak traced to Colorado cantaloupes, the U.S. Centers for Disease Control and Prevention ( CDC) said Wednesday.The number of people sickened by the tainted cantaloupes has reached 123 in 26 states, with Pennsylvania reporting its first case. One of the ill patients, a pregnant woman, suffered a miscarriage, the CDC said in a telebriefing.The listeria outbreak has been the most deadly one since 1998, according to the CDC.Listeria is a common bacterium that typically causes mild illness in healthy people, but can cause severe illness in older people and those with compromised immune systems. It also can cause miscarriages and stillbirths in pregnant women and severe infections in new babies.The CDC estimates that about 48 million people in the U.S. each year get sick from tainted food, with about 128,000 hospitalized and 3,000 deaths.